- Home
- ZYME vs DBD Comparison
ZYME vs DBD Comparison
Compare ZYME & DBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZYME | DBD |
|---|---|---|
| Founded | 2003 | 1859 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.1B |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | ZYME | DBD |
|---|---|---|
| Price | $25.80 | $65.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 3 |
| Target Price | $28.50 | ★ $76.67 |
| AVG Volume (30 Days) | ★ 1.8M | 194.7K |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43573.14 |
| EPS | N/A | ★ 1.35 |
| Revenue | $134,481,000.00 | ★ $3,690,400,000.00 |
| Revenue This Year | $64.45 | $2.72 |
| Revenue Next Year | $67.04 | $2.15 |
| P/E Ratio | ★ N/A | $48.61 |
| Revenue Growth | ★ 116.21 | N/A |
| 52 Week Low | $9.03 | $34.88 |
| 52 Week High | $28.49 | $67.02 |
Technical Indicators
Market Signals| Indicator | ZYME | DBD |
|---|---|---|
| Relative Strength Index (RSI) | 63.18 | 60.67 |
| Support Level | $24.83 | $64.23 |
| Resistance Level | $27.49 | $67.00 |
| Average True Range (ATR) | 1.32 | 1.85 |
| MACD | -0.03 | 0.04 |
| Stochastic Oscillator | 60.00 | 86.71 |
Price Performance
Historical ComparisonAbout ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About DBD Diebold Nixdorf Incorporated Common stock
Diebold Nixdorf Inc is engaged in providing software and hardware services for financial and retail industries. The customer segments of the company are Banking, which offers integrated solutions for financial institutions, and Retail, which offers solutions, software, and services that improve the checkout process for retailers. A majority of its revenue is generated from the Banking segment. Geographically, the company generates maximum revenue from Europe, Middle East, and Africa (EMEA), followed by the Americas and the Asia-Pacific region.